Skip to content

Medical emergency? What to do

UK reviews controversial curbs on Alzheimer drugs

3-RXPublished December 21, 20053 min read

Key points

  • British healthcare experts meet on Tuesday to review a planned ban on the new use of Alzheimer's drugs within the state health service, which has outraged both patients and drug companies.
  • A negative opinion from NICE could deter other countries from using the drugs, which cost around 1,000 pounds ($1,765) per patient a year, some experts believe.
  • NICE decided in a preliminary ruling earlier this year that so-called anti-cholinesterase drugs -- which offer no cure but can help some patients -- were not cost effective.
  • "We've don't think these drugs are clinically cost effective, based on the evidence we have seen," said NICE spokeswoman Lucy Betterton.

British healthcare experts meet on Tuesday to review a planned ban on the new use of Alzheimer's drugs within the state health service, which has outraged both patients and drug companies.

The deliberations of the National Institute of Clinical Excellence (NICE) committee will resonate with governments around the world, who increasingly have to weigh up the benefits of modern medicines against their price.

A negative opinion from NICE could deter other countries from using the drugs, which cost around 1,000 pounds ($1,765) per patient a year, some experts believe.

Alzheimer's is a growing problem around the globe, with a team of international researchers predicting last week the number of people suffering from dementia was set to double every 20 years and could reach more than 81 million worldwide by 2040.

NICE decided in a preliminary ruling earlier this year that so-called anti-cholinesterase drugs -- which offer no cure but can help some patients -- were not cost effective.

But it put off implementing the ban on using the pills in newly diagnosed Alzheimer's patients pending more evidence on their potential benefits in certain patients.

"We've don't think these drugs are clinically cost effective, based on the evidence we have seen," said NICE spokeswoman Lucy Betterton.

"But if drug manufacturers have got additional data that might identify sub-groups of patients that particularly benefit, we would like to see it and we have asked them to submit it."

The agency, which was founded in 1999 to examine the cost-benefit of drugs and surgical procedures, is expected to announce its final decision in January.

The ongoing debate leaves in limbo the future of four drugs, including Pfizer Inc and Eisai Co Ltd's market leader Aricept, which are currently reimbursed on the National Health Service.

The other medicines affected are Reminyl, from Johnson & Johnson and Shire Pharmaceuticals Group Plc, and Novartis AG's Exelon, both of which are used like Aricept to treat mild to moderate Alzheimer's.

The fourth drug, Ebixa, is made by Lundbeck and is given to patients with more serious disease.

DRUG FIRMS FIGHTS BACK

Drug manufacturers have come out fighting.

Pfizer and Eisai said in a statement that a re-analysis of data undertaken for NICE suggested Aricept was actually more cost effective than previously thought, because even "non-responders" maintained cognition levels after six months on the drug, while those on placebo saw a decline.

But clinical trial results showed it was not possible to accurately predict in advance which patients would benefit, as NICE had hoped, the companies added.

As a result, Pfizer and Eisai said all patients should be offered the chance of benefiting from medication.

Britain's Alzheimer's Society said it would be "outrageous" if anti-cholinesterase drugs -- already licensed as safe and effective by regulators -- were not reimbursed.

The Association for the British Pharmaceutical Industry said rejection of the medicines by NICE would be a major blow.

"What is the point of investing further money into this area of research if the end result of your labours, which satisfied the licensing agency, is not going to be prescribed?" said spokesman Richard Ley.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.